Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients (Q56985092)

Filippo Trapani

0 references

Sara Tedeschi

Sara Tedeschi

0 references

Leonardo Calza

Leonardo Calza

0 references

Roberto Manfredi

Roberto Manfredi

0 references

Vincenzo Colangeli

Vincenzo Colangeli

0 references

author name string

Benedetta Piergentili

0 references

language of work or name

English

0 references

publication date

August 2011

0 references

1 April 2011

1 reference

National Center for Biotechnology Information

PubMed publication ID

21453205

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21453205

full work available at URL

28 November 2024

http://www.tandfonline.com/doi/pdf/10.3109/00365548.2011.572906

1 reference

10.3109/00365548.2011.572906

DOI

https://api.crossref.org/works/10.3109/00365548.2011.572906

28 November 2024

0 references

0 references

0 references

656-60

0 references

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

The nephrotoxic effects of HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906

Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2011.572906